617 related articles for article (PubMed ID: 34028936)
1. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
2. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
[TBL] [Abstract][Full Text] [Related]
3. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer.
Vernocchi P; Gili T; Conte F; Del Chierico F; Conta G; Miccheli A; Botticelli A; Paci P; Caldarelli G; Nuti M; Marchetti P; Putignani L
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227982
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
[TBL] [Abstract][Full Text] [Related]
7. Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis.
Lu H; Gao NL; Tong F; Wang J; Li H; Zhang R; Ma H; Yang N; Zhang Y; Wang Y; Liang Z; Zeng H; Chen WH; Dong X
Microbiol Spectr; 2021 Dec; 9(3):e0080221. PubMed ID: 34787462
[TBL] [Abstract][Full Text] [Related]
8. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
[TBL] [Abstract][Full Text] [Related]
10. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
11. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Huang J; Liu D; Wang Y; Liu L; Li J; Yuan J; Jiang Z; Jiang Z; Hsiao WW; Liu H; Khan I; Xie Y; Wu J; Xie Y; Zhang Y; Fu Y; Liao J; Wang W; Lai H; Shi A; Cai J; Luo L; Li R; Yao X; Fan X; Wu Q; Liu Z; Yan P; Lu J; Yang M; Wang L; Cao Y; Wei H; Leung EL
Gut; 2022 Apr; 71(4):734-745. PubMed ID: 34006584
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
Zhang F; Ferrero M; Dong N; D'Auria G; Reyes-Prieto M; Herreros-Pomares A; Calabuig-Fariñas S; Duréndez E; Aparisi F; Blasco A; García C; Camps C; Jantus-Lewintre E; Sirera R
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34063829
[TBL] [Abstract][Full Text] [Related]
13. The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.
Yin H; Yang L; Peng G; Yang K; Mi Y; Hu X; Hao X; Jiao Y; Wang X; Wang Y
Cancer Biol Med; 2021 May; 18(4):1040-52. PubMed ID: 33960176
[TBL] [Abstract][Full Text] [Related]
14. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.
Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
[TBL] [Abstract][Full Text] [Related]
16. Promising predictors of checkpoint inhibitor response in NSCLC.
Alex F; Alfredo A
Expert Rev Anticancer Ther; 2020 Nov; 20(11):931-937. PubMed ID: 32870120
[TBL] [Abstract][Full Text] [Related]
17. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
[TBL] [Abstract][Full Text] [Related]
18.
Tomita Y; Goto Y; Sakata S; Imamura K; Minemura A; Oka K; Hayashi A; Jodai T; Akaike K; Anai M; Hamada S; Iyama S; Saruwatari K; Saeki S; Takahashi M; Ikeda T; Sakagami T
Oncoimmunology; 2022; 11(1):2081010. PubMed ID: 35655708
[TBL] [Abstract][Full Text] [Related]
19. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiota in Lung Cancer: Where Do We Stand?
Georgiou K; Marinov B; Farooqi AA; Gazouli M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]